
Opinion|Videos|May 30, 2024
Adverse Effects and Management with Ruxolitinib
Author(s)Prithviraj Bose, MD
Dr. Bose discusses the potential adverse effects associated with ruxolitinib therapy and how they should be managed in this patient, with a focus on addressing the risk of anemia and other hematologic adverse effects.
Advertisement
Episodes in this series

Now Playing
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
4
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
5


















